Kegyes, D.* , Constantinescu, C.* , Vrancken, L., Rasche, L., Grégoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C., & Caers, J. (07 June 2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? Journal of Hematology and Oncology, 15 (1), 78. doi:10.1186/s13045-022-01296-2 * These authors have contributed equally to this work. |
Caers, J., Duray, E., Vrancken, L., Marcion, G., Bocuzzi, V., De Veirman, K., Krasniqi, A., Lejeune, M., Withofs, N., Devoogdt, N., Dumoulin, M., Karlström, A. E., & D'Huyvetter, M. (2022). Radiotheranostic Agents in Hematological Malignancies. Frontiers in Immunology, 13, 911080. doi:10.3389/fimmu.2022.911080 |
Vrancken, L., Lejeune, M., PIROTTE, M., Duray, E., Köse, M. C., BEGUIN, Y., & CAERS, J. (2021). Le myélome multiple : un tour d’horizon des nouveautés dans sa biologie et son traitement. Revue Médicale de Liège, 76, 482-488. |
Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007 |
Faict, S., Muller, J., De Veirman, K., De Bruyne, E., Maes, K., Vrancken, L., Heusschen, R., De Raeve, H., Schots, R., Vanderkerken, K., Caers, J., & Menu, E. (2018). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal, 8 (11), 105. doi:10.1038/s41408-018-0139-7 |
Vercruyssen, M., Vrancken, L., & CAERS, J. (2018). What is new in MGUS and smoldering multiple myeloma. Belgian Journal of Hematology, 9, 2-7. |